Federal Circuit Examines Jurisdiction Over Patent Arbitration in Acorda’s $16.6M Award Dispute

The Federal Circuit panel recently deliberated on its authority over arbitration appeals involving patent law, as it examines Acorda Therapeutics Inc.’s efforts to augment a $16.6 million arbitral award in a dispute with Alkermes PLC. The contention revolves around a multiple sclerosis drug, highlighting the complexities of arbitration in patent-related matters. At least one judge expressed skepticism regarding the panel’s jurisdiction to consider Acorda’s claim. For further details on the proceedings, the [original article](https://www.law360.com/articles/2350332/fed-circ-weighs-purview-over-acorda-s-17m-arbitral-award) is available.